Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Young

Showing results (71-80 of 104) with videos related to

Pageof 11
Sort By:
Cancer Cytopathology|September 1, 2022
Rapid On-site Evaluation Practice Variability Appraisal (ROSE PETAL) surveySameer K Avasarala, Maroun Matta, Jaspal Singh, et al.
The Lancet. Infectious Diseases|October 25, 2011
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trialJan van Lunzen, Franco Maggiolo, José R Arribas, et al.
BMC Infectious Diseases|February 20, 2025
Social contacts and mixing patterns in rural GambiaIsaac Osei, Emmanuel Mendy, Kevin van Zandvoort, et al.
HIV/AIDS (Auckland, N.Z.)|April 21, 2017
Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeksKathleen E Squires, Benjamin Young, Lizette Santiago, et al.
AIDS (London, England)|January 12, 2012
Immune reconstitution inflammatory syndrome: incidence and implications for mortalityRichard M Novak, James T Richardson, Kate Buchacz, et al.
AIDS (London, England)|July 9, 2010
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patientsKathleen E Squires, Benjamin Young, Edwin Dejesus, et al.
The Journal of Infectious Diseases|November 4, 2005
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjectsJoel E Gallant, Allan E Rodriguez, Winkler G Weinberg, et al.
AIDS and Behavior|November 8, 2022
The Influence of Anticipated HIV Stigma on Health-related Behaviors, Self-rated Health, and Treatment Preferences Among People Living with HIV in East AsiaFei Yu, Yu-Hsiang Hsiao, Sejun Park, et al.
AIDS and Behavior|August 5, 2020
Shared Decision Making Between Patients and Healthcare Providers and its Association with Favorable Health Outcomes Among People Living with HIVChinyere Okoli, Garry Brough, Brent Allan, et al.
Preventive Medicine|June 29, 2020
Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countriesPatricia de Los Rios, Chinyere Okoli, Yogesh Punekar, et al.
Pageof 11

Showing results (71-80 of 104) with videos related to

Sort By:
Pageof 11
Cancer Cytopathology|September 1, 2022
Rapid On-site Evaluation Practice Variability Appraisal (ROSE PETAL) surveySameer K Avasarala, Maroun Matta, Jaspal Singh, et al.
The Lancet. Infectious Diseases|October 25, 2011
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trialJan van Lunzen, Franco Maggiolo, José R Arribas, et al.
BMC Infectious Diseases|February 20, 2025
Social contacts and mixing patterns in rural GambiaIsaac Osei, Emmanuel Mendy, Kevin van Zandvoort, et al.
HIV/AIDS (Auckland, N.Z.)|April 21, 2017
Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeksKathleen E Squires, Benjamin Young, Lizette Santiago, et al.
AIDS (London, England)|January 12, 2012
Immune reconstitution inflammatory syndrome: incidence and implications for mortalityRichard M Novak, James T Richardson, Kate Buchacz, et al.
AIDS (London, England)|July 9, 2010
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patientsKathleen E Squires, Benjamin Young, Edwin Dejesus, et al.
The Journal of Infectious Diseases|November 4, 2005
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjectsJoel E Gallant, Allan E Rodriguez, Winkler G Weinberg, et al.
AIDS and Behavior|November 8, 2022
The Influence of Anticipated HIV Stigma on Health-related Behaviors, Self-rated Health, and Treatment Preferences Among People Living with HIV in East AsiaFei Yu, Yu-Hsiang Hsiao, Sejun Park, et al.
AIDS and Behavior|August 5, 2020
Shared Decision Making Between Patients and Healthcare Providers and its Association with Favorable Health Outcomes Among People Living with HIVChinyere Okoli, Garry Brough, Brent Allan, et al.
Preventive Medicine|June 29, 2020
Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countriesPatricia de Los Rios, Chinyere Okoli, Yogesh Punekar, et al.
Pageof 11